• 研究課題をさがす
  • 研究者をさがす
  • KAKENの使い方
  1. 前のページに戻る

中枢神経疾患治療を目指した血液脳関門透過型人工ナノ粒子の創製

研究課題

研究課題/領域番号 20J20737
研究種目

特別研究員奨励費

配分区分補助金
応募区分国内
審査区分 小区分90120:生体材料学関連
研究機関北海道大学

研究代表者

Abd Elwakil Mahmoud  北海道大学, 生命科学院, 特別研究員(PD)

研究期間 (年度) 2020-04-24 – 2023-03-31
研究課題ステータス 採択後辞退 (2022年度)
配分額 *注記
3,400千円 (直接経費: 3,400千円)
2022年度: 1,100千円 (直接経費: 1,100千円)
2021年度: 1,100千円 (直接経費: 1,100千円)
2020年度: 1,200千円 (直接経費: 1,200千円)
キーワードmRNA drugs / ionizable polyesters / Gene Therapy / Organocatalysis / Lipid Nanoparticles / Lung diseases / Combinatorial chemistry / Immunotherapy / Biomaterials
研究開始時の研究の概要

The general outline of my research includes three main principles
1. Directed evolution of nanocarriers for specific non liver gene delivery.
2. Establishment of rapid and robust screening method to enable in vivo reprogramming of specific cells or tissues on-demand.
3. Understand the biology of CNS delivery and discover the associated endogenous proteins.
Upon having a proof of concept for the previously mentioned concepts, we can introduce a new exciting era for nucleic acid therapeutics. Understanding of those three core principles we will lead to evolve a new field namely; Nanoinformatics.

研究実績の概要

During the past year I have developed a novel platform for mRNA delivery beyond the hepatocytes referred as to ionizable polyester/polyether RNA-Transporters (iPORT LNP). The key findings for the past year are:
1. Development of ionizable lipo-polyether RNA transporters (iPORTs) that are produced via the organocatalytic ring-opening polymerization of glycidylamine monomers using steroidal initiators. Interestingly, the tacticity of the iPORTs had a significant impact on in vitro and in vivo RNA delivery efficiency and tropism and this impact was dependent of monomeric structure. The top performing Estriol-GA05-30 iPORT LNPs elicited strong antitumor activity in a therapeutic, prophylactic model and were well-tolerated in mice. This technology is being filed as a patent through Hokkaido University. Additionally a manuscript has been submitted to JACS, Manuscript ID: ja-2022-017103).
2. Development of ionizable polyester RNA-Transporters LNP that selectively transfect splenocytes and lungs after systemic administration. The results of this project is being filed as a patent through Hokkaido University as well. Furthermore, a manuscript is being prepared for submission to publications.

現在までの達成度 (区分)
現在までの達成度 (区分)

2: おおむね順調に進展している

理由

Although we are at very hard times during COVID-19, my research projects were going very well and research output was really great because:
1. I have submitted two patents in one year.
2. Two manuscripts were prepared and are being submitted for publication in top tier scientific journals.

今後の研究の推進方策

In the coming year I plan to:
1. Apply my mRNA iPORT LNP technology for therapeutic application in lung diseases, cancer immunotherapy and infectious diseases vaccines such as COVID-19.
2. Extend my combinatorial chemistry for RNA delivery for other hard tissues such as bone and central nervous system.
3. Communicate my iPORT LNP technology with scientific community via attending international conferences and big pharmaceutical companies.

報告書

(2件)
  • 2021 実績報告書
  • 2020 実績報告書
  • 研究成果

    (2件)

すべて 2021 2020

すべて 雑誌論文 (1件) (うち査読あり 1件) 産業財産権 (1件)

  • [雑誌論文] Engineered e-decalactone lipomers by-pass the liver to selectively in vivo deliver mRNA to the lungs without targeting ligands2021

    • 著者名/発表者名
      Elwakil A, Gao T, Isono T, Sato Y, Elewa Y, Satoh T, Harashima H,
    • 雑誌名

      Mater Horizons

      巻: 8 号: 8 ページ: 2251-2259

    • DOI

      10.1039/d1mh00185j

    • 関連する報告書
      2021 実績報告書
    • 査読あり
  • [産業財産権] Engineered polyesters for mRNA delivery to the lungs2020

    • 発明者名
      佐藤敏文、磯野拓也、A.E.Mahmoud、佐藤悠介、原島秀吉
    • 権利者名
      北海道大学
    • 産業財産権種類
      特許
    • 出願年月日
      2020
    • 関連する報告書
      2020 実績報告書

URL: 

公開日: 2020-07-07   更新日: 2024-03-26  

サービス概要 検索マニュアル よくある質問 お知らせ 利用規程 科研費による研究の帰属

Powered by NII kakenhi